Release Date	January 30, 2026
Expiration Date	January 30, 2027
Format	Webcast
CME	1.0 credit
CE	1.0 contact hour

Acknowledgement

This activity is provided by Talem Health and RME Collaborative.
     
This activity is supported by an independent medical education grant from Bristol Myers Squibb.

Credit Available

• Physicians — maximum of 1.0 AMA PRA Category 1 Credit™
• Nurses — 1.0 Contact Hour (0.5 contact hour of pharmacotherapy credit)
• Pharmacists — 1.0 Contact Hour (0.1 CEU)

All other healthcare professionals completing this course will be issued a statement of participation.

Target Audience

This activity is designed specifically for community cardiologists, nurse practitioners, physician assistants, and pharmacists who care for patients from rural and underserved communities.  

Program Overview

Hypertrophic cardiomyopathy (HCM) poses a complex challenge for cardiologists caring for patients in rural and underserved communities. Since the disease presents similarly to other conditions, misdiagnosis or delayed diagnosis are common. Management is further complicated by health disparities, including long travel distances to care and limited access to HCM specialists, which can contribute to delayed treatment and suboptimal outcomes. This on-demand CME/CE activity will review the clinical presentation of HCM, best practices for conducting a comprehensive history and physical examination, and recommendations for diagnostic testing. Expert faculty will also highlight the latest clinical guidance on current and emerging HCM therapies and discuss the role of team-based strategies and shared decision-making in expanding access to high-quality HCM care in rural and underserved settings. 

The content for this enduring activity was recorded during a live webinar on December 19, 2025.

Learning Objectives

Upon completion of this activity, participants should be better able to: 

• Apply the diagnostic criteria and recommend tests to facilitate early diagnosis and intervention for hypertrophic cardiomyopathy 
• Evaluate current and emerging treatments for obstructive hypertrophic cardiomyopathy based on their mechanisms of action, efficacy, and safety profiles 
• Employ team-based strategies and shared decision-making to improve equitable access to hypertrophic cardiomyopathy care 

Faculty

Anjali T. Owens, MD
Medical Director, Center for Inherited Cardiac Disease
Associate Professor of Medicine 
University of Pennsylvania, Perelman School of Medicine
Philadelphia, PA


Kevin G. Lax, MD
Cardiologist 
Penn Medicine Doylestown Health Cardiology
Doylestown, PA

Joint Accreditation Statement

In support of improving patient care, Talem Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation Statement

Physician Continuing Medical Education
Talem Health designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. Designated for 0.5 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.

Continuing Pharmacy Education
Talem Health designates this continuing education activity for 1.0 contact hour (0.1 CEU) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number – JA4008332-0000-26-026-H01-P)
Type of Activity: Application

Disclosure of Conflicts of Interest

Talem Health adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All identified conflicts of interest are thoroughly vetted and mitigated according to Talem Health policy. Talem Health is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

All relevant financial relationships have been mitigated.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Faculty

Anjali T. Owens, MD, has disclosed the following relevant financial relationships: consultant/advisory board member for Alexion Pharmaceuticals, Inc., Avidity Biosciences, Inc., Bayer AG, BridgeBio Pharma, Inc., Bristol Myers Squibb, Cytokinetics, Inc., Imbria Pharmaceuticals, Kardigan, Lexeo Therapeutics, Inc., Stealth BioTherapeutics, Inc., and Tenaya Therapeutics; grant/research support (awarded to institution) from Bristol Myers Squibb. 

Kevin G. Lax, MD, has no relevant financial relationships to disclose.

Planners, Managers, and Reviewer

The Talem Health planners, managers, and reviewer have nothing to disclose.

Instructions for Participation and Credit

This activity is offered at no cost to participants. To receive CME credit, participants must:

1. Read the CME/CE information, including learning objectives and disclosure statements.
2. Complete the pre-test.
3. View the online activity.
4. Complete the post-test and evaluation form.

A post-test score of 67% or higher is required to obtain credit. Your certificate will be made available for immediate download.

Course Viewing Requirements

Supported Browsers:   
Desktop/laptop: Newest and last prior version of Google Chrome, Firefox, Safari, and Microsoft Edge   

Mobile devices: Newest and last prior version of Safari and Google Chrome   

Supported Phones & Tablets:   
All devices 

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

©RME Collaborative, a division of Talem Health, LLC. All Rights Reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Talem Health, LLC is prohibited.

Media

Internet activity

Fee Information

There is no fee for this educational activity.

Contact Information

For questions about this activity, please contact RME Collaborative (a division of Talem Health) at 800-913-9370 or cme@cmeruralhealth.com.